Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort

Table 3 Predictors of functional benefit (MELD score decrease) following antiviral therapy based on patient baseline characteristics

Baseline parameters	MELD decrease		P value (univariable)	P value (multivariable3)	OR (95%CI)
	Yes (n = 78, 44%)	No (n = 101, 56%)
Age (yr)	59 ± 9	59 ± 9	0.9781	0.815	0.996 (0.961-1.032)
Child-Pugh A	53 (38)	86 (62)	0.0062	0.592	1.327 (0.472-3.725)
Child-Pugh B/C	25 (62)	15 (38)
MELD	10 ± 3	8 ± 3	< 0.0011	0.082	1.177 (0.980-1.414)
Creatinine (mg/dL)	0.8 ± 0.3	0.9 ± 0.8	0.3441	-	-
Platelets (/nL)	104 ± 56	126 ± 64	0.0141	0.617	0.998 (0.992-1.005)
Albumin (g/L)	36.7 ± 5.2	39.9 ± 4.9	< 0.0011	0.057	0.928 (0.860-1.002)
Bilirubin (mg/dL)	1.6 ± 1.0	1.1 ± 0.8	< 0.0011	0.739	1.096 (0.638-1.883)

Data are expressed as n (%) or means ± SD (range). Baseline and follow-up data at 12 wk after the end of treatment was available for n = 179 patients.

¹t-test;

²Chi-square-test;

³Multivariable logistic regression.